| Identification | Back Directory | [Name]
Urea, N-[(3S,4R)-4-(3-fluorophenyl)-1-(2-methoxyethyl)-3-pyrrolidinyl]-N'-[4-methyl-3-(2-methyl-5-pyrimidinyl)-1-phenyl-1H-pyrazol-5-yl]- | [CAS]
1824664-89-2 | [Synonyms]
hTrkA-IN-1
anizatrectinib
Anizatrectinib/hTrkA-IN-1
1-((3S,4R)-4-(3-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-3-(2-methylpyrimidin-5-yl)-1-phenyl-1H-pyrazol-5-yl)urea
Urea, N-[(3S,4R)-4-(3-fluorophenyl)-1-(2-methoxyethyl)-3-pyrrolidinyl]-N'-[4-methyl-3-(2-methyl-5-pyrimidinyl)-1-phenyl-1H-pyrazol-5-yl]-
Urea, N-[(3S,4R)-4-(3-fluorophenyl)-1-(2-methoxyethyl)-3-pyrrolidinyl]-N'-[4-methyl-3-(2-methyl-5-pyrimidinyl)-1-phenyl-1H-pyrazol-5-yl]- | [Molecular Formula]
C29H32FN7O2 | [MOL File]
1824664-89-2.mol | [Molecular Weight]
529.61 |
| Hazard Information | Back Directory | [Uses]
Anizatrectinib (hTrkA-IN-1) is a potent and orally active inhibitor of TrkA kinase with an IC50 of 1.3 nM, compound 2 extracted from patent WO2015175788. Anizatrectinib can be used for the study of inflammatory disease, such as prostatitis, pelvic, et al[1]. | [IC 50]
TrkA | [References]
[1] Shelley Allen, et al. 1-((3s,4r)-4-(3-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-3-(2-methylpyrimidin-5-yl)-1-phenyl-1h-pyrazol-5-yl)urea as a trka kinase inhibitor. Patent WO2015175788A1. |
|
|